App and coaching help men stick with HIV prevention pill
NCT ID NCT05072093
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a program to help men who have sex with men (MSM) stay on daily PrEP (a pill that prevents HIV) and reduce sexually transmitted infections (STIs). 240 men in Atlanta used a mobile app that flagged when they might stop PrEP, then a peer counselor and doctor stepped in to offer support. The study also offered on-demand PrEP (taking pills only around sex) and long-acting injectable PrEP as alternatives. Participants were followed for up to 2 years to see if they stayed on PrEP and how many got STIs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PrEP (Truvada) and on-demand PrEP
What this could lead to
If successful, this approach could help men at risk for HIV stay on PrEP longer and reduce sexually transmitted infections.
What could go wrong
This is a completed Phase 4 study with 240 participants in one city, so results may not apply to everyone. The intervention relies on app use and counseling, which may not work for all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PRISM Research Center
Atlanta, Georgia, 30322, United States